1
|
Ladetto M, Tavarozzi R, Zanni M, Evangelista A, Ferrero S, Tucci A, Botto B, Bolis S, Volpetti S, Zilioli VR, Puccini B, Arcari A, Pavone V, Gaidano G, Corradini P, Tani M, Cavallo F, Milone G, Ghiggi C, Pinto A, Pastore D, Ferreri AJM, Latte G, Patti C, Re F, Benedetti F, Luminari S, Pennese E, Bossi E, Boccomini C, Anastasia A, Bottelli C, Ciccone G, Vitolo U. Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase III trial. Ann Oncol 2024; 35:118-129. [PMID: 37922989 DOI: 10.1016/j.annonc.2023.10.095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2023] [Revised: 09/11/2023] [Accepted: 10/03/2023] [Indexed: 11/07/2023] Open
Abstract
BACKGROUND Optimal consolidation for young patilents with relapsed/refractory (R/R) follicular lymphoma (FL) remains uncertain in the rituximab era, with an unclear benefit of autologous stem cell transplantation (ASCT). The multicenter, randomized, phase III FLAZ12 (NCT01827605) trial compared anti-CD20 radioimmunotherapy (RIT) with ASCT as consolidation after chemoimmunotherapy, both followed by rituximab maintenance. PATIENTS AND METHODS Patients (age 18-65 years) with R/R FL and without significant comorbidities were enrolled and treated with three courses of conventional, investigator-chosen chemoimmunotherapies. Those experiencing at least a partial response were randomized 1 : 1 to ASCT or RIT before CD34+ collection, and all received postconsolidation rituximab maintenance. Progression-free survival (PFS) was the primary endpoint. The target sample size was 210 (105/group). RESULTS Between August 2012 and September 2019, of 164 screened patients, 159 were enrolled [median age 57 (interquartile range 49-62) years, 55% male, 57% stage IV, 20% bulky disease]. The study was closed prematurely because of low accrual. Data were analyzed on 8 June 2023, on an intention-to-treat basis, with a 77-month median follow-up from enrollment. Of the 141 patients (89%), 70 were randomized to ASCT and 71 to RIT. The estimated 3-year PFS in both groups was 62% (hazard ratio 1.11, 95% confidence interval 0.69-1.80, P = 0.6662). The 3-year overall survival also was similar between the two groups. Rates of grade ≥3 hematological toxicity were 94% with ASCT versus 46% with RIT (P < 0.001), and grade ≥3 neutropenia occurred in 94% versus 41%, respectively (P < 0.001). Second cancers occurred in nine patients after ASCT and three after radioimmunotherapy (P = 0.189). CONCLUSIONS Even if prematurely discontinued, our study did not demonstrate the superiority of ASCT versus RIT. ASCT was more toxic and demanding for patients and health services. Both strategies yielded similar, favorable long-term outcomes, suggesting that consolidation programs milder than ASCT require further investigation in R/R FL.
Collapse
Affiliation(s)
- M Ladetto
- Department of Translational Medicine, University of Eastern Piedmont, Novara; SCDU di Ematologia, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria.
| | - R Tavarozzi
- Department of Translational Medicine, University of Eastern Piedmont, Novara; SCDU di Ematologia, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria
| | - M Zanni
- SCDU di Ematologia, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria
| | - A Evangelista
- SSD of Clinical Epidemiology, Universitaria Città della Salute e della Scienza di Torino and Centre for Cancer Prevention Piemonte, Torino
| | - S Ferrero
- Department of Molecular Biotechnologies and Health Sciences, Universitaria Città della Salute e della Scienza di Torino and Centre for Cancer Prevention Piemonte, Torino
| | - A Tucci
- Department of Hematology, Spedali Civili, Brescia
| | - B Botto
- Struttura Complessa Ematologia, AOU Città della salute e della scienza di Torino, Turin
| | - S Bolis
- SC Ematologia ASST-Monza, Monza
| | - S Volpetti
- Division of Hematology, Clinica Ematologica, Centro Trapianti e Terapie Cellulari Carlo Melzi, DISM, Azienda Ospedaliero Universitaria S. M. Misericordia, Udine
| | - V R Zilioli
- Division of Haematology, ASST Grande Ospedale Metropolitano Niguarda, Milano
| | - B Puccini
- Department of Haematology, University of Florence, Firenze
| | - A Arcari
- Hematology Unit, Ospedale Guglielmo da Saliceto, Piacenza
| | - V Pavone
- A. O. C. Panico-U.O.C Ematologia e Trapianto, Tricase, Lecce
| | - G Gaidano
- SCDU di Ematologia, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria; Division of Hematology, Azienda Ospedaliero-Universitaria Maggiore della Carità, Novara
| | - P Corradini
- Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milan, Milano
| | - M Tani
- Hematology Unit, Department of Oncology and Hematology, "Santa Maria delle Croci" Hospital, Ravenna
| | - F Cavallo
- Department of Molecular Biotechnologies and Health Sciences, Universitaria Città della Salute e della Scienza di Torino and Centre for Cancer Prevention Piemonte, Torino
| | - G Milone
- Division of Hematology and Program for Hematopoietic Transplantation, Azienda Ospedaliera Policlinico Vittorio Emanuele, Catania
| | - C Ghiggi
- Hematology Division, IRCCS Azienda Ospedaliera Universitaria San Martino, IST Istituto Nazionale per la Ricerca sul Cancro, Genova
| | - A Pinto
- Department of Hematology, Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico "Fondazione G Pascale", Naples
| | | | - A J M Ferreri
- Onco-Hematology Department, Fondazione Centro San Raffaele, Milano
| | - G Latte
- Unità di Ematologia e Trapianto di Midollo Osseo, San Francesco Hospital, Nuoro
| | - C Patti
- Divisione di Oncoematologia, Azienda Villa Sofia - Cervello, Palermo
| | - F Re
- Department of Hematology, A.O.U. di Parma, Parma
| | - F Benedetti
- Department of Medicine, Section of Hematology and Bone Marrow Transplant Unit, University of Verona, Verona
| | - S Luminari
- Department of Hematology, IRCCS Reggio Emilia, Reggio Emilia
| | - E Pennese
- Lymphoma Unit, Department of Hematology, Ospedale Spirito Santo, Pescara
| | - E Bossi
- SC Ematologia ASST-Monza, Monza
| | - C Boccomini
- Struttura Complessa Ematologia, AOU Città della salute e della scienza di Torino, Turin
| | - A Anastasia
- Department of Hematology, Spedali Civili, Brescia
| | - C Bottelli
- Department of Hematology, Spedali Civili, Brescia
| | - G Ciccone
- SSD of Clinical Epidemiology, Universitaria Città della Salute e della Scienza di Torino and Centre for Cancer Prevention Piemonte, Torino
| | - U Vitolo
- Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy
| |
Collapse
|
2
|
Zanni M, Brogi R, Merli E, Apollonio M. The wolf and the city: insights on wolves conservation in the anthropocene. Anim Conserv 2023. [DOI: 10.1111/acv.12858] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Affiliation(s)
- M. Zanni
- Department of Veterinary Medicine University of Sassari Sassari Italy
| | - R. Brogi
- Department of Veterinary Medicine University of Sassari Sassari Italy
| | - E. Merli
- Department of Veterinary Medicine University of Sassari Sassari Italy
| | - M. Apollonio
- Department of Veterinary Medicine University of Sassari Sassari Italy
| |
Collapse
|
3
|
Monici L, Djuric O, Muraca A, Verona C, Bergonzini E, Venturelli F, Zanni M, Vicentini M, Giorgi Rossi P, Tegani P, Marchesi C. A COVID-19-Dedicated Facility for the Care of Older Adults During a Health Emergency: An Italian Experience. J Aging Soc Policy 2022:1-9. [PMID: 35950841 DOI: 10.1080/08959420.2022.2110809] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2020] [Accepted: 12/15/2021] [Indexed: 10/15/2022]
Abstract
Older adults living in long-term care facilities (LTCF) are particularly vulnerable to COVID-19. We describe the clinical characteristics, the course of disease, and the care needs of 38 non-self-sufficient adults with COVID-19 in an LTCF specially set up for those who could not be discharged home or to a standard LTCF. Residents spent an average of 30.5 days in the facility (range 4-77 days). Most of them recovered and were discharged home or to their LTCF of origin. It seems feasible to set up dedicated facilities to treat and provide assistance in the activities of daily living to older adults with COVID-19.
Collapse
Affiliation(s)
- Lucia Monici
- Primary Care Department, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy
| | - Olivera Djuric
- Epidemiology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy
- Center for Environmental, Nutritional and Genetic Epidemiology (CREAGEN), Section of Public Health, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy
| | - Anna Muraca
- Primary Care Department, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy
| | | | - Eleonora Bergonzini
- Primary Care Department, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy
| | - Francesco Venturelli
- Epidemiology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy
- Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy
| | - Marco Zanni
- Primary Care Department, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy
| | - Massimo Vicentini
- Epidemiology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy
| | - Paolo Giorgi Rossi
- Epidemiology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy
| | - Patrizia Tegani
- Elderly Assistance Service, Azienda Unità Sanitaria Locale di Reggio Emilia - IRCCS, Reggio Emilia, Italy
| | - Cristina Marchesi
- Medical Director of the Azienda Unità Sanitaria Locale-IRCCS Di Reggio Emilia, Reggio Emilia, Italy
| |
Collapse
|
4
|
Kolossváry M, deFilippi C, Lu M, Zanni M, Fulda E, Foldyna B, Ribaudo H, Mayrhofer T, Collier A, Bloomfield G, Fichtenbaum C, Overton E, Aberg J, Currier J, Fitch K, Douglas P, Grinspoon S. 463 Proteomic Signature Of Early Coronary Artery Disease In People With Hiv: Analysis Of The Reprieve Mechanistic Substudy. J Cardiovasc Comput Tomogr 2022. [DOI: 10.1016/j.jcct.2022.06.074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
5
|
Affiliation(s)
- D E Tripoloni
- División Emergencias, División Cirugía General, Sanatorio "Dr. Julio Méndez", Avellaneda 551, Ciudad Autónoma de Buenos Aires, República Argentina.
| | - M I Canaro García
- División Emergencias, División Cirugía General, Sanatorio "Dr. Julio Méndez", Avellaneda 551, Ciudad Autónoma de Buenos Aires, República Argentina
| | - F Cassani
- División Emergencias, División Cirugía General, Sanatorio "Dr. Julio Méndez", Avellaneda 551, Ciudad Autónoma de Buenos Aires, República Argentina
| | - M Zanni
- División Emergencias, División Cirugía General, Sanatorio "Dr. Julio Méndez", Avellaneda 551, Ciudad Autónoma de Buenos Aires, República Argentina
| |
Collapse
|
6
|
Grizzetti B, Vigiak O, Udias A, Aloe A, Zanni M, Bouraoui F, Pistocchi A, Dorati C, Friedland R, De Roo A, Benitez Sanz C, Leip A, Bielza M. How EU policies could reduce nutrient pollution in European inland and coastal waters. Glob Environ Change 2021; 69:102281. [PMID: 34471331 PMCID: PMC8386246 DOI: 10.1016/j.gloenvcha.2021.102281] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/08/2020] [Revised: 04/09/2021] [Accepted: 04/16/2021] [Indexed: 05/23/2023]
Abstract
Intensive agriculture and densely populated areas represent major sources of nutrient pollution for European inland and coastal waters, altering the aquatic ecosystems and affecting their capacity to provide ecosystem services and support economic activities. Ambitious water policies are in place in the European Union (EU) for protecting and restoring aquatic ecosystems under the Water Framework Directive and the Marine Strategy Framework Directive. This research quantified the current pressures of point and diffuse nitrogen and phosphorus emissions to European fresh and coastal waters (2005-2012), and analysed the effects of three policy scenarios of nutrient reduction: 1) the application of measures currently planned in the Rural Development Programmes and under the Urban Waste Water Treatment Directive (UWWTD); 2) the full implementation of the UWWTD and the absence of derogations in the Nitrates Directive; 3) high reduction of nutrient, using best technologies in wastewaters treatment and optimal fertilisation in agriculture. The results of the study show that for the period 2005-2012, the nitrogen load to European seas was 3.3-4.1 TgN/y and the phosphorus load was 0.26-0.30 TgP/y. Policy measures supporting technological improvements (third scenario) could decrease the nutrient export to the seas up to 14% for nitrogen and 20% for phosphorus, improving the ecological status of rivers and lakes, but widening the nutrient imbalance in coastal ecosystems (i.e. increasing nitrogen availability with respect to phosphorus), affecting eutrophication. Further nutrient reductions could be possible by a combination of measures especially in the agricultural sector. However, without tackling current agricultural production and consumption system, the reduction might not be sufficient for achieving the goals of EU water policy in some regions. The study analysed the expected changes and the source contribution in different European regional seas, and highlights the advantages of addressing the land-sea dynamics, checking the coherence of measures taken under different policies.
Collapse
Affiliation(s)
- B. Grizzetti
- European Commission Joint Research Centre (JRC), Ispra, VA, Italy
| | - O. Vigiak
- European Commission Joint Research Centre (JRC), Ispra, VA, Italy
| | - A. Udias
- European Commission Joint Research Centre (JRC), Ispra, VA, Italy
| | | | | | - F. Bouraoui
- European Commission Joint Research Centre (JRC), Ispra, VA, Italy
| | - A. Pistocchi
- European Commission Joint Research Centre (JRC), Ispra, VA, Italy
| | | | - R. Friedland
- European Commission Joint Research Centre (JRC), Ispra, VA, Italy
| | - A. De Roo
- European Commission Joint Research Centre (JRC), Ispra, VA, Italy
| | | | - A. Leip
- European Commission Joint Research Centre (JRC), Ispra, VA, Italy
| | | |
Collapse
|
7
|
Tucci A, Musuraca G, Cavallo F, Zilioli VR, Zanni M, Pelliccia S, Mannina D, Michieli M, Vallisa D, Tani M, Merli F, Re F, Marcheselli L, Campostrini G, Pagani C, Grimaldi D, Liardo EV, Re A, Cox MC, Rossi G. AUTOLOGOUS TRANSPLANT IN ELDERLY PATIENTS WITH R/R AGGRESSIVE LYMPHOMA SELECTED BY SIMPLIFIED CGA: THE RECANZ PROSPECTIVE PHASE 2 STUDY BY THE FONDAZIONE ITALIANA LINFOMI. Hematol Oncol 2021. [DOI: 10.1002/hon.99_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- A Tucci
- ASST Spedali Civili Brescia Hematology Division Brescia Italy
| | - G Musuraca
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" Hematology Unit Meldola (FC) Italy
| | - F Cavallo
- University of To‐rino/AOU “Città della Salute e della Scienza di Torino” Division of Hematology, Department of Molecular Biotechnologies and Health Sciences Torino Italy
| | - V. R Zilioli
- ASST Grande Ospedale Metropolitano Niguarda Division of Hematology Milano Italy
| | - M Zanni
- A.O. SS. Antonio e Biagio e Cesare Arrigo Division of Hematology Alessandria Italy
| | - S Pelliccia
- Hospital Sant’Andrea – Sapienza, Rome Hematology University Roma Italy
| | - D Mannina
- Azienda Ospedaliera Papardo Unit of Hematology Messina Italy
| | - M Michieli
- Aviano (PN) Haematology Transplant and Cell Therapy Unit Aviano (PN) Italy
| | - D Vallisa
- Ospedale Guglielmo da Saliceto Division of Hematology Piacenza Italy
| | - M Tani
- Ospedale delle Croci Department of Hematology Ravenna Italy
| | - F Merli
- Azienda Unità Sanitaria Locale – IRCCS Hematology Unit Reggio Emilia Italy
| | - F Re
- AOU di Parma Hematology Unit Parma Italy
| | - L Marcheselli
- Fondazione Italiana Linfomi Onlus Fondazione Italiana Linfomi Onlus Modena Italy
| | - G Campostrini
- ASST Spedali Civili Brescia Hematology Division Brescia Italy
| | - C Pagani
- ASST Spedali Civili Brescia Hematology Division Brescia Italy
| | - D Grimaldi
- University of To‐rino/AOU “Città della Salute e della Scienza di Torino” Division of Hematology, Department of Molecular Biotechnologies and Health Sciences Torino Italy
| | - E. V Liardo
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" Hematology Unit Meldola (FC) Italy
| | - A Re
- ASST Spedali Civili Brescia Hematology Division Brescia Italy
| | - M. C Cox
- University Hospital Sant’Andrea – Sapienza Hematology Roma Italy
| | - G Rossi
- ASST Spedali Civili Brescia Hematology Division Brescia Italy
| |
Collapse
|
8
|
Pulsoni A, Tosti ME, Ferrero S, Luminari S, Dondi A, Liberati AM, Cenfra N, Renzi D, Zanni M, Boccomini C, Ferreri AJ, Rattotti S, Zilioli VR, Bernuzzi P, Bolis S, Musuraca G, Nassi L, Perrone T, Stelitano C, Anastasia A, Corradini P, Partesotti G, Re F, Cencini E, Mannarella C, Mannina D, Molinari AL, Tani M, Annechini G, Assanto GM, Grapulin L, Guarini A, Cavalli M, De Novi LA, Ciabatti E, Mantoan B, Della Starza I, Arcaini L, Ricardi U, Gattei V, Galimberti S, Ladetto M, Foà R, Del Giudice I. UPDATED RESULTS OF THE FIL “MIRO” STUDY, A MULTICENTER PHASE II TRIAL COMBINING LOCAL RADIOTHERAPY AND MRD‐DRIVEN IMMUNOTHERAPY IN EARLY‐STAGE FOLLICULAR LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.31_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- A. Pulsoni
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - M. E. Tosti
- Istituto Superiore di Sanità National Center for Global Health Roma Italy
| | - S. Ferrero
- Hematology Division University of Torino/AOU "Città della Salute e della Scienza di Torino" Department of Molecular Biotechnologies and Health Sciences Torino Italy
| | - S. Luminari
- Hematology Unit Arcispedale S. Maria Nuova, Azienda Unità Sanitaria Locale ‐ IRCCS, University of Modena and Reggio Emilia Reggio Emilia Italy
| | - A. Dondi
- Fondazione Italiana Linfomi Onlus, (FIL) Modena Italy
| | - A. M. Liberati
- A.O. Santa Maria Terni, University of Perugia Perugia Italy
| | - N. Cenfra
- Hematology Unit, S. Maria Goretti Hospital AUSL Latina Latina Italy
| | - D. Renzi
- Hematology and Stem Cells Transplantation Unit IRCCS Istituto Nazionale dei Tumori Regina Elena Roma Italy
| | - M. Zanni
- Division of Hematology, SS. Antonio e Biagio Hospital Alessandria Italy
| | - C. Boccomini
- Hematology Department Città della Salute e della Scienza Torino Italy
| | - A. J. Ferreri
- Lymphoma Unit IRCCS San Raffaele Scientific Institute Department of Onco‐Haematology Milano Italy
| | - S. Rattotti
- Division of Hematology Fondazione IRCCS Policlinico San Matteo Pavia Italy
| | - V. R. Zilioli
- Division of Hematology ASST Grande Ospedale Metropolitano Niguarda Milano Italy
| | - P. Bernuzzi
- Hematology Unit, Guglielmo da Saliceto Hospital Department of Onco‐Hematology Piacenza Italy
| | - S. Bolis
- Hematology Department ASST San Gerardo University Hospital Monza Italy
| | - G. Musuraca
- Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori” Meldola (FC) Italy
| | - L. Nassi
- Division of Hematology University of Eastern Piedmont Department of Translational Medicine Novara Italy
| | - T. Perrone
- Unit of Hematology with Transplantation University of Bari, Dept. of Emergency and Organ Transplantation Bari Italy
| | - C. Stelitano
- Department of Haematology Azienda Ospedaliera Bianchi Melacrino Morelli Reggio Calabria Italy
| | - A. Anastasia
- Hematology, ASST Spedali Civili di Brescia Brescia Italy
| | - P. Corradini
- Division of Hematology Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Milano Italy
| | - G. Partesotti
- Onco‐Hematology Department Nuovo ospedale civile of Sassuolo Sassuolo Italy
| | - F. Re
- Hematology Clinic, A.O.U. di Parma Parma Italy
| | - E. Cencini
- Unit of Hematology Azienda Ospedaliera Universitaria Senese & University of Siena Siena Italy
| | - C. Mannarella
- Hematology Unit "Madonna delle Grazie" Hospital Matera Italy
| | - D. Mannina
- Department of Hematology Azienda Ospedaliera Papardo Messina Italy
| | | | - M. Tani
- Hematology Unit Santa Maria delle Croci Hospital Ravenna Italy
| | - G. Annechini
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - G. M. Assanto
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - L. Grapulin
- Department of Radiotherapy Policlinico Umberto I, Sapienza University Roma Italy
| | - A. Guarini
- Hematology, Sapienza University Department of Molecular Medicine Roma Italy
| | - M. Cavalli
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - L. A. De Novi
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - E. Ciabatti
- Section of Hematology, University of Pisa Department of Clinical and Experimental Medicine Pisa Italy
| | - B. Mantoan
- Hematology Division University of Torino Department of Molecular Biotechnologies and Health Sciences Torino Italy
| | - I. Della Starza
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - L. Arcaini
- Division of Hematology, Fondazione IRCCS Policlinico San Matteo University of Pavia, Department of Molecular Medicine Pavia Italy
| | - U. Ricardi
- Radiation Oncology, University of Turin Department of Oncology Torino Italy
| | - V. Gattei
- Clinical and Experimental Onco‐Hematology Unit CRO Aviano National Cancer Institute Aviano Italy
| | - S. Galimberti
- Section of Hematology University of Pisa, Department of Clinical and Experimental Medicine Pisa Italy
| | - M. Ladetto
- Hematology, Az Ospedaliera Santi Antonio e Biagio e Cesare Arrigo Università del Piemonte Orientale Alessandria Italy
| | - R. Foà
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - I. Del Giudice
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| |
Collapse
|
9
|
Chiappella A, Carniti C, Re A, Castellino C, Evangelista A, Ciancia R, Orsucci L, Pinto A, Usai SV, Arcari A, Ilariucci F, Rossi FG, Benedetti F, Flenghi L, Ghiggi C, Molinari AL, Stefoni V, Volpetti S, Zilioli VR, Ballerini F, Bruna R, Cavallo F, Musuraca G, Patti C, Re F, Tani M, Varettoni M, Zanni M, Dodero A, Pileri SA, Ciccone G, Corradini P. ROMIDEPSIN‐CHOEP PLUS UP‐FRONT STEM‐CELL TRANSPLANTATION IN PERIPHERAL T‐CELL LYMPHOMA (PTCL): FIRST ANALYSIS OF THE PHASE II FIL‐PTCL13 STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.130_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- A. Chiappella
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Hematology and Stem Cell Transplantation Milano Italy
| | - C. Carniti
- Fondazione IRCCS, Istituto Nazionale dei Tumori di Milano Laboratory of Hematology Division of Hematology and Stem Cell Transplantation Milano Italy
| | - A. Re
- ASST Spedali Civili di Brescia Hematology Division Brescia Italy
| | - C. Castellino
- Azienda Ospedaliera S. Croce e Carle Division of Hematology Cuneo Italy
| | - A. Evangelista
- Azienda Ospedaliera e Universitaria Città della Salute e della Scienza and CPO Piemonte Unit of Clinical Epidemiology Torino Italy
| | - R. Ciancia
- Centro di Riferimento Oncologico (CRO) IRCCS Onco‐hematology and Stem Cell Transplantation and Cellular Therapies Aviano Italy
| | - L. Orsucci
- Azienda Ospedaliera e Universitaria Città della Salute e della Scienza Division of Hematology Torino Italy
| | - A. Pinto
- Istituto Nazionale Tumori, Fondazione G. Pascale, IRCCS Hematology‐Oncology & Stem Cell Transplantation Unit Napoli Italy
| | - S. V. Usai
- Ospedale Oncologico Armando Businco Hematology Cagliari Italy
| | - A. Arcari
- Ospedale Guglielmo da Saliceto Hematology Unit Piacenza Italy
| | - F. Ilariucci
- Azienda USL‐IRCCS, Hematology Reggio Emilia Italy
| | - F. G. Rossi
- Fondazione IRCCS Cà Granda OM Policlinico Division of Hematology Milano Italy
| | - F. Benedetti
- Azienda Ospedaliera Universitaria di Verona Hematology and Stem Cell Transplantation Verona Italy
| | - L. Flenghi
- Azienda Ospedaliera di Perugia Hematology Perugia Italy
| | - C. Ghiggi
- IRCCS Ospedale Policlinico San Martino Hematology Genova Italy
| | | | - V. Stefoni
- University of Bologna Institute of Hematology "Seràgnoli" Bologna Italy
| | - S. Volpetti
- Presidio Ospedaliero Universitario "Santa Maria della Misericordia” di Udine ASUFC Clinic of Hematology Udine Italy
| | - V. R. Zilioli
- ASST Grande Ospedale Metropolitano Niguarda Division of Hematology Milano Italy
| | - F. Ballerini
- IRCCS Ospedale Policlinico San Martino Clinic of Hematology Genova Italy
| | - R. Bruna
- Ospedale Maggiore Della Carità Division of Hematology Novara Italy
| | - F. Cavallo
- University of Torino Azienda Ospedaliera e Universitaria Città della Salute e della Scienza Division of Hematology Department of Molecular Biotechnologies and Health Sciences Torino Italy
| | - G. Musuraca
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" Division of Hematology Meldola Italy
| | - C. Patti
- Azienda Villa Sofia Cervello Division of Onco‐Hematology Palermo Italy
| | - F. Re
- Azienda Ospedaliera‐Universitaria di Parma Hematology and CTMO Parma Italy
| | - M. Tani
- Ospedale Santa Maria delle Croci Hematology Unit Ravenna Italy
| | - M. Varettoni
- Fondazione IRCCS Policlinico San Matteo Division of Hematology Pavia Italy
| | - M. Zanni
- Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo Division of Hematology Alessandria Italy
| | - A. Dodero
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Hematology and Stem Cell Transplantation Milano Italy
| | - S. A. Pileri
- European Institute of Oncology IRCCS Division of Haematopathology Milano Italy
| | - G. Ciccone
- Azienda Ospedaliera e Universitaria Città della Salute e della Scienza and CPO Piemonte Unit of Clinical Epidemiology Torino Italy
| | - P. Corradini
- Chair of Hematology University of Milano Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Division of Hematology and Stem Cell Transplantation Milano Italy
| |
Collapse
|
10
|
Ferrero S, Moia R, Cascione L, Zaccaria GM, Rinaldi A, Alessandria B, Grimaldi D, Favini C, Evangelista A, Schipani M, Narni F, Stelitano C, Stefani PM, Benedetti F, Mian M, Casaroli I, Zanni M, Castellino C, Pavone V, Galimberti S, Re F, Rossi D, Cortelazzo S, Gaidano G, Ladetto M, Bertoni F. A COMPLETELY GENETIC PROGNOSTIC MODEL OVERCOMES CLINICAL PROGNOSTICATORS IN MANTLE CELL LYMPHOMA: RESULTS FROM THE MCL0208 TRIAL FROM THE FONDAZIONE ITALIANA LINFOMI (FIL). Hematol Oncol 2021. [DOI: 10.1002/hon.59_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- S. Ferrero
- Hematology Department of Molecular Biotechnologies and Health Sciences University of Torino Hematology 1, AOU "Città della salute e della scienza di Torino" Torino Italy
| | - R. Moia
- Division of Hematology Department of Translational Medicine Università del Piemonte Orientale Novara Italy
| | - L. Cascione
- Institute of Oncology Research Faculty of Biomedical Sciences USI, Bellinzona SIB Swiss Institute of Bioinformatics Lausanne Switzerland
| | - G. M. Zaccaria
- Hematology and Cell Therapy Unit IRCCS Istituto Tumori 'Giovanni Paolo II' Bari Italy
| | - A. Rinaldi
- Institute of Oncology Research Faculty of Biomedical Sciences USI Bellinzona Switzerland
| | - B. Alessandria
- Hematology Department of Molecular Biotechnologies and Health Sciences University of Torino Torino Italy
| | - D. Grimaldi
- Hematology Department of Molecular Biotechnologies and Health Sciences University of Torino Torino Italy
| | - C. Favini
- Division of Hematology Department of Translational Medicine Università del Piemonte Orientale Novara Italy
| | - A. Evangelista
- Unit of Cancer Epidemiology CPO Piemonte A.O.U. Città della Salute e della Scienza di Torino Torino Italy
| | - M. Schipani
- Division of Hematology Department of Translational Medicine Università del Piemonte Orientale Novara Italy
| | - F. Narni
- Department of Medical and Surgical Sciences Section of Hematology University of Modena and Reggio Emilia Azienda Ospedaliero Universitaria Policlinico Modena Italy
| | - C. Stelitano
- Hematology Department AO "Bianchi‐Melacrino‐Morelli" Reggio Calabria Italy
| | - P. M. Stefani
- Hematology Unit General Hospital Ca' Foncello Treviso Italy
| | - F. Benedetti
- Hematology University Division Verona Hospital Verona Italy
| | - M. Mian
- Department of Haematology and CBMT Bolzano Hospital Bolzano Italy
| | - I. Casaroli
- Haematology Unit ASST Monza San Gerardo Monza Italy
| | - M. Zanni
- Hematology Unit Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo Alessandria Italy
| | - C. Castellino
- Department of Hematology S. Croce e Carle Hospital Cuneo Italy
| | - V. Pavone
- UOC Ematologia e Trapianto Az. Osp. C. Panico Tricase Italy
| | - S. Galimberti
- Section of Hematology Department of Clinical and Experimental Medicine University of Pisa Pisa Italy
| | - F. Re
- Haematology and Bone Marrow Transplant Unit Parma General Hospital Parma Italy
| | - D. Rossi
- Institute of Oncology Research Faculty of Biomedical Sciences USI, Bellinzona, Switzerland Oncology Institute of Southern Switzerland (IOSI) Bellinzona,Bellinzona Switzerland
| | - S. Cortelazzo
- Oncology Unit Italy Medical & Center Hospital Humanitas Gavazzeni and Castelli Bergamo Italy
| | - G. Gaidano
- Division of Hematology Department of Translational Medicine Università del Piemonte Orientale Novara Italy
| | - M. Ladetto
- Division of Hematology Department of Translational Medicine Università del Piemonte Orientale Novara, Division of Hematology Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo Alessandria Italy
| | - F. Bertoni
- Institute of Oncology Research Faculty of Biomedical Sciences USI, Bellinzona, Switzerland Oncology Institute of Southern Switzerland (IOSI) Bellinzona,Bellinzona Switzerland
| |
Collapse
|
11
|
Merli F, Tucci A, Arcari A, Rigacci L, Cavallo F, Cabras G, Alvarez I, Fabbri A, Re A, Ferrero S, Puccini B, Usai SV, Ferrari A, Cencini E, Pennese E, Zilioli VR, Marino D, Balzarotti M, Cox MC, Zanni M, Rocco A, Lleshi A, Botto B, Hohaus S, Merli M, Sartori R, Gini G, Nassi L, Musuraca G, Tani M, Bottelli C, Kovalchuk S, Re F, Flenghi L, Molinari A, Tarantini G, Chimienti E, Marcheselli L, Mammi C, Luminari S, Spina M. THE ELDERLY PROGNOSTIC INDEX (EPI) PREDICTS EARLY MORTALITY IN OLDER PATIENTS WITH DLBCL. A SUBSTUDY OF THE ELDERLY PROJECT BY THE FONDAZIONE ITALIANA LINFOMI (FIL). Hematol Oncol 2021. [DOI: 10.1002/hon.85_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
12
|
Trentadue G, Pinto R, Salvetti M, Zanni M, Pliakostathis K, Scholz H, Martini G. Assessment of Low-Frequency Magnetic Fields Emitted by DC Fast Charging Columns. Bioelectromagnetics 2020; 41:308-317. [PMID: 32043629 PMCID: PMC7217217 DOI: 10.1002/bem.22254] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2019] [Accepted: 01/31/2020] [Indexed: 11/24/2022]
Abstract
The expected imminent widespread use of electromobility in transport systems draws attention to the possible effects of human exposure to magnetic fields generated inside electric vehicles and during their recharge. The current trend is to increase the capacity of the battery inside the vehicles to extend the available driving range and to increase the power of recharging columns to reduce the time required for a full recharge. This leads to higher currents and potentially stronger magnetic fields. The Interoperability Center of the Joint Research Center started an experimental activity focused on the assessment of low‐frequency magnetic fields emitted by five fast‐charging devices available on the market in recharge and standby conditions. The aim of this study was to contribute to the development of a standard measurement procedure for the assessment of magnetic fields emitted by direct current charging columns. The spectrum and amplitudes of the magnetic field, as well as exposure indices according to guidelines for the general public and occupational exposure, were recorded by means of a magnetic field probe analyzer. The worst‐case scenario for instantaneous physical direct and indirect effects was identified. Measurements within the frequency range of 25 Hz–2 kHz revealed localized magnetic flux density peaks above 100 μT at the 50 Hz frequency in three out of five chargers, registered in close proximity during the recharge. Beyond this distance, exposure indices were recorded showing values below 50% of reference levels. Bioelectromagnetics. 2020;41:308–317 © 2020 The Authors. Bioelectromagnetics published by Wiley Periodicals, Inc.
Collapse
Affiliation(s)
| | - Rosanna Pinto
- ENEA-Italian National Agency for New Technologies, Energy and Sustainable Economic Development, RC Casaccia, Rome, Italy
| | - Marco Salvetti
- European Commission, Joint Research Center (JRC), Ispra, Italy
| | - Marco Zanni
- European Commission, Joint Research Center (JRC), Ispra, Italy
| | | | - Harald Scholz
- European Commission, Joint Research Center (JRC), Ispra, Italy
| | - Giorgio Martini
- European Commission, Joint Research Center (JRC), Ispra, Italy
| |
Collapse
|
13
|
Barachetti L, Zanni M, Stefanello D, Rampazzo A. Use of four-layer porcine small intestinal submucosa alone as a scaffold for the treatment of deep corneal defects in dogs and cats: preliminary results. Vet Rec 2020; 186:e28. [PMID: 31937546 DOI: 10.1136/vr.105513] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2019] [Revised: 10/20/2019] [Accepted: 12/05/2019] [Indexed: 01/18/2023]
Abstract
BACKGROUND To describe the efficacy of four-layer porcine small intestinal submucosa (Vetrix BioSIS plus+) as single scaffold for the treatment of deep corneal lesions in dogs and cats. METHODS 10 dogs and 3 cats with deep or full thickness corneal defects were treated surgically with BioSIS plus graft. Corneal transparency scores and vision were evaluated. RESULTS Lesions in dogs were four perforations, three descemetoceles, two limbal melanocytomas and one deep corneal ulcer. In cats, there were one limbal melanocytoma and two perforations. The average length of the follow-up was 86 days. In all, 12 out of 13 eyes treated were visual at last recheck (92.3 per cent). The scars were mild eight cases (66.7 per cent), but denser in four cases (33.4 per cent). Complication were partial collagenolysis in three cases (25 per cent), which resolved with medical therapy, mild corneal pigmentation in one case (8.4 per cent) and anterior synechia in one case (8.4 per cent). One case experienced severe collagenolysis and was enucleated 21 days postoperatively. CONCLUSIONS Four-layer porcine SIS graft was successfully used for surgical treatment of deep corneal lesions in selected corneal diseases in a small series of dogs and cats, with good results in terms of mechanic support and corneal transparency.
Collapse
Affiliation(s)
- Laura Barachetti
- Department of Veterinary Medicine, University of Milan, Milan, Italy .,Dipartimento di Oftalmologia, Istituto Veterinario di Novara, Granozzo con Monticello, Italy
| | - Marco Zanni
- Department of Veterinary Science and Public Health, University of Milan, Milan, Italy
| | | | - Antonella Rampazzo
- Equine Department, Universitat Zurich Vetsuisse-Fakultat, Zurich, Switzerland
| |
Collapse
|
14
|
Balzarotti M, Ricardi U, Spina M, Monagheddu C, Tucci A, Cavallo F, Zanni M, Arcari A, Rusconi C, Sartori R, Merli F, Re F, Vitolo U, Dessi D, Melis L, Gaidano G, Chiti A, Deidda M, Santoro A, Ciccone G, Chauvie S, Cabras M. PET-DRIVEN RADIOTHERAPY IN PATIENTS WITH LOW RISK DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): THE DLCL10 MULTICENTER PHASE 2 TRIAL BY FONDAZIONE ITALIANA LINFOMI (FIL). Hematol Oncol 2019. [DOI: 10.1002/hon.62_2630] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- M. Balzarotti
- Medical Oncology and Hematology; Humanitas Clinical and Research Hospital-IRCCS-Humanitas University; Rozzano Milano Italy
| | - U. Ricardi
- Radiotherapy; AOU Città della Salute e della Scienza, University of Torino; Torino Italy
| | - M. Spina
- Medical Oncology; IRCCS CRO; Aviano (PN) Italy
| | - C. Monagheddu
- Epidemiologia Clinica e Valutativa; AOU Città della Salute e della Scienza e CPO; Torino Italy
| | - A. Tucci
- Hematology; Spedali Civili; Brescia
| | - F. Cavallo
- Hematology; Universita' Citta' della Salute e della Scienza; Torino Italy
| | - M. Zanni
- Hematology; ASO ss Antonio e Biagio e Arrigo; Alessandria Italy
| | - A. Arcari
- Hematology; Ospedale Guglielmo da Saliceto; Piacenza Italy
| | - C. Rusconi
- Hemtaology; ASST Grande Ospedale Metropolitano Niguarda; Milano Italy
| | - R. Sartori
- Hematology; Azienda ULSS 2 Marca Trevigiana; Castelfranco Veneto Treviso Italy
| | - F. Merli
- Hematology; Arcispedale Santa Maria Nuova; Reggio Emilia Italy
| | - F. Re
- Hematology; AOU Parma; Parma Italy
| | - U. Vitolo
- Hematology; AO Città della Salute e della Scienza; Torino Italy
| | - D. Dessi
- Hematology; Ospedale Oncologico Armando Businco; Cagliari Italy
| | - L. Melis
- Nuclear Medicine; Ospedale Oncologico Armando Businco; Cagliari Italy
| | - G. Gaidano
- Hematology; AOU Maggiore della Carità di Novara; Novara Italy
| | - A. Chiti
- Nuclear Medicine; Humanitas Clinical and Research Hospital-IRCCS - Humanitas University; Rozzano Milano Italy
| | - M. Deidda
- Radiotherapy; Ospedale Oncologico Armando Businco; Cagliari Italy
| | - A. Santoro
- Medical Oncology and Hematology; Humanitas Clinical and Research Hospital-IRCCS-Humanitas University; Rozzano Milano Italy
| | - G. Ciccone
- Epidemiologia Clinica e Valutativa; AOU Città della Salute e della Scienza e CPO; Torino Italy
| | - S. Chauvie
- Medical Physics; Santa Croce e Carle Hospital; Cuneo Italy
| | - M. Cabras
- Hematology; Ospedale Oncologico Armando Businco; Cagliari Italy
| |
Collapse
|
15
|
Chiappella A, Carniti C, Evangelista A, Re A, Cabras M, Stefoni V, Castellino C, Congiu A, Pinto A, Zanni M, Rusconi C, Molinari A, Ciancia R, Baldini L, Nassi L, Re F, Tani M, Ilariucci F, Cavallo F, Santoro A, Volpetti S, Dodero A, Pileri S, Ciccone G, Corradini P. PHASE II FIL-PTCL13 STUDY OF ROMIDEPSIN-CHOEP FOLLOWED BY HIGH-DOSE CHEMOTHERAPY AND TRANSPLANTATION IN UNTREATED PERIPHERAL T-CELL LYMPHOMAS. Hematol Oncol 2019. [DOI: 10.1002/hon.3_2632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- A. Chiappella
- Ematologia; AOU Città della Salute e della Scienza di Torino; Torino Italy
| | - C. Carniti
- Ematologia; Università degli Studi di Milano; Milano Italy
| | - A. Evangelista
- SSD Epidemiologia Clinica e Valutativa; Clinical Trial Center, AOU Città della Salute e della Scienza di Torino e CPO Piemonte; Torino Italy
| | - A. Re
- Ematologia; ASTT Spedali Civili di Brescia; Brescia Italy
| | - M.G. Cabras
- Ematologia; Ospedale Oncologico Armando Businco; Cagliari Italy
| | - V. Stefoni
- Ematologia; Policlinico S.Orsola-Malpighi, Istituto di Ematologia "Seragnoli"; Bologna Italy
| | - C. Castellino
- Ematologia e Trapianto di Midollo Osseo; AO Santa Croce e Carle; Cuneo Italy
| | - A.G. Congiu
- Ematologia; Ospedale Policlinico San Martino S.S.R.L. - IRCCS per l'Oncologia; Genova Italy
| | - A. Pinto
- Ematologia Oncologica; Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale; Napoli Italy
| | - M. Zanni
- Ematologia; AO SS Antonio e Biagio e Cesare Arrigo; Alessandria Italy
| | - C. Rusconi
- Ematologia; ASST Grande Ospedale Metropolitano Niguarda; Milano Italy
| | | | - R. Ciancia
- Oncoematologia; trapianti emopoietici e terapie cellulari, Centro di Riferimento Oncologico CRO, IRCCS; Aviano Italy
| | - L. Baldini
- Ematologia; Ospedale Maggiore Policlinico - Fondazione IRCCS Ca' Granda; Milano Italy
| | - L. Nassi
- Ematologia; AOU Maggiore della Carità di Novara; Novara Italy
| | - F. Re
- Ematologia e CTMO; AOU Ospedale Maggiore di Parma; Parma Italy
| | - M. Tani
- Ematologia; Ospedale Santa Maria delle Croci; Ravenna Italy
| | - F. Ilariucci
- Ematologia; Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS; Reggio Emilia Italy
| | - F. Cavallo
- Ematologia; Università degli Studi - AOU Città della Salute e della Scienza di Torino; Torino Italy
| | - A. Santoro
- Ematologia; Istituto Clinico Humanitas; Rozzano Italy
| | - S. Volpetti
- Ematologia; ASUI Santa Maria della Misericordia; Udine Italy
| | - A. Dodero
- Ematologia; Fondazione IRCCS Istituto Nazionale dei Tumori; Milano Italy
| | - S.A. Pileri
- Emopatologia; Istituto Europeo Oncologico IRCCS; Milano Italy
| | - G. Ciccone
- SSD Epidemiologia Clinica e Valutativa; Clinical Trial Center, AOU Città della Salute e della Scienza di Torino e CPO Piemonte; Torino Italy
| | - P. Corradini
- Ematologia; Fondazione IRCCS Istituto Nazionale dei Tumori - Università degli Studi di Milano; Milano Italy
| |
Collapse
|
16
|
Tarella C, Zanni M, Rambaldi A, Benedetti F, Passera R, Gianni AM. xxx. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.8123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8123 Background: The high-dose sequential (HDS) chemotherapy approach, including early dose-intensification and autograft with peripheral blood progenitor cells (PBPC), was introduced several years ago (Gianni & Bonadonna, 1989); subsequently, it has been broadly used in the management of both non-Hodgkin s (NHL) and Hodgkin s Lymphoma (HL). The outcome of a large series of lymphoma patients treated with the HDS approach at 10 GITIL Centers is reported. Methods: Data have been collected on 1,266 patients, who received either the original or slightly modified HDS regimens. There were 213 HL and 1,053 NHL (630 intermediate/high-grade, 423 low-grade); median age was 46 yrs. Overall, 671 (53%) patients had refractory/relapsed disease, 595 (47%) were at diagnosis. Most patients were autografted with PBPC; 158 (12%) patients did not undergo autografting due to toxicity, disease progression or poor harvests. Results: Overall, 1,013 (80%) patients reached Complete Remission (CR) following HDS. As to December 2006, 93 (7%) patients died for early/late toxicities, 328 (26%) died for lymphoma, 844 are known to be alive. At a lead follow-up of 18 years, and a median follow-up of 5 yrs, the 5-yr Overall Survival (OS) projection is 64% (S.E.: 2%). The long-term survival was quite favorable in patients achieving a Complete Remission (CR), with a 5-yr OS projection of 76%. The prolonged OS in patients achieving CR was consistent in all lymphoma subtypes, i.e. both low and high-grade NHL (5-yr OS: 77% in both), and HL (5-yr OS: 72%). Patients at diagnosis had a significantly better outcome compared to patients treated for relapsed/refractory disease, again CR achievement was associated with prolonged survival in both subgroups (82% and 69%, respectively, at 5 yrs.). On multivariate Cox survival analysis, CR achievement was the most powerful predictor of long-term survival (HR 0.13, c.i.: 0.10–0.17). Lastly, achieving substantial tumor reduction before autografting had a major influence on the clinical outcome. Conclusions: 1. the HDS program is feasible in a multicenter setting; 2. the long-term outcome is well influenced by the CR status after HDS; 3. the influence of CR achievement on the long-term survival holds true in all lymphoma subtypes, including indolent lymphomas; 4. an adequate pre-autograft tumor debulking may contribute to a favorable long-term outcome. [Table: see text]
Collapse
Affiliation(s)
- C. Tarella
- Gruppo Italiano Terapie Innovative Linfomi (GITIL); Divisione Universitaria di Ematologia, Torino, Italy; Divisione di Ematologia, Bergamo, Italy; Divisione Universitaria di Ematologia, Verona, Italy; Divisione Universitaria Medicina Nucleare, Torino, Italy; Divisione Universitaria Oncologia, Milano, Italy
| | - M. Zanni
- Gruppo Italiano Terapie Innovative Linfomi (GITIL); Divisione Universitaria di Ematologia, Torino, Italy; Divisione di Ematologia, Bergamo, Italy; Divisione Universitaria di Ematologia, Verona, Italy; Divisione Universitaria Medicina Nucleare, Torino, Italy; Divisione Universitaria Oncologia, Milano, Italy
| | - A. Rambaldi
- Gruppo Italiano Terapie Innovative Linfomi (GITIL); Divisione Universitaria di Ematologia, Torino, Italy; Divisione di Ematologia, Bergamo, Italy; Divisione Universitaria di Ematologia, Verona, Italy; Divisione Universitaria Medicina Nucleare, Torino, Italy; Divisione Universitaria Oncologia, Milano, Italy
| | - F. Benedetti
- Gruppo Italiano Terapie Innovative Linfomi (GITIL); Divisione Universitaria di Ematologia, Torino, Italy; Divisione di Ematologia, Bergamo, Italy; Divisione Universitaria di Ematologia, Verona, Italy; Divisione Universitaria Medicina Nucleare, Torino, Italy; Divisione Universitaria Oncologia, Milano, Italy
| | - R. Passera
- Gruppo Italiano Terapie Innovative Linfomi (GITIL); Divisione Universitaria di Ematologia, Torino, Italy; Divisione di Ematologia, Bergamo, Italy; Divisione Universitaria di Ematologia, Verona, Italy; Divisione Universitaria Medicina Nucleare, Torino, Italy; Divisione Universitaria Oncologia, Milano, Italy
| | - A. M. Gianni
- Gruppo Italiano Terapie Innovative Linfomi (GITIL); Divisione Universitaria di Ematologia, Torino, Italy; Divisione di Ematologia, Bergamo, Italy; Divisione Universitaria di Ematologia, Verona, Italy; Divisione Universitaria Medicina Nucleare, Torino, Italy; Divisione Universitaria Oncologia, Milano, Italy
| |
Collapse
|
17
|
Tarella C, Zanni M, Di Nicola M, Patti C, Calvi R, Pescarollo A, Zoli V, Fornari A, Novero D, Cabras A, Stella M, Comino A, Remotti D, Ponzoni M, Caracciolo D, Ladetto M, Magni M, Devizzi L, Rosato R, Boccadoro M, Bregni M, Corradini P, Gallamini A, Majolino I, Mirto S, Gianni AM. Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). Leukemia 2007; 21:1802-11. [PMID: 17554382 DOI: 10.1038/sj.leu.2404781] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
A prospective multicenter program was performed to evaluate the combination of rituximab and high-dose (hd) sequential chemotherapy delivered with multiple autologous peripheral blood progenitor cell (PBPC) support (R-HDS-maps regimen) in previously untreated patients with diffuse large B-cell lymphoma (DLB-CL) and age-adjusted International Prognostic Score (aaIPI) score 2-3. R-HDS-maps includes: (i) three APO courses; (ii) sequential administration of hd-cyclophosphamide (CY), hd-Ara-C, both supplemented with rituximab, hd-etoposide/cisplatin, PBPC harvests, following hd-CY and hd-Ara-C; (iii) hd-mitoxantrone (hd-Mito)/L-Pam + 2 further rituximab doses; (iv) involved-field radiotherapy. PBPC rescue was scheduled following Ara-C, etoposide/cisplatin and Mito/L-Pam. Between 1999 and 2004, 112 consecutive patients aged <65 years (74 score 2, 38 score 3) entered the study protocol. There were five early and two late toxic deaths. Overall 90 patients (80%) reached clinical remission (CR); at a median 48 months follow-up, 87 (78%) patients are alive, 82 (73%) in continuous CR, with 4 year overall survival (OS) and event-free survival (EFS) projections of 76% (CI 68-85%) and 73% (CI 64-81%), respectively. There were no significant differences in OS and EFS between subgroups with Germinal-Center and Activated B-cell phenotype. Thus, life expectancy of younger patients with aaIPI 2-3 DLB-CL is improved with the early administration of rituximab-supplemented intensive chemotherapy compared with the poor outcome following conventional chemotherapy.
Collapse
Affiliation(s)
- C Tarella
- Dip Medicina-Oncologia Sperimentale, Divisione Universitaria di Ematologia, Torino, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Zanni M, Magni M, Rambaldi A, Benedetti F, Rosato R, Passera R, Patti K, Ciceri F, Gallamini A, Cortelazzo S, Majolino I, Mirto S, Corradini P, Boccadoro M, Andreini A, Barbui T, Gianni A, Tarella C. P010 Incidence and risk factors of secondary myelodysplastic syndrome/acute leukemia occurrence following peripheral blood progenitor cell autograft: a GITIL (Gruppo Italiano Terapie Innovative Nei Linfomi) survey on 1266 lymphoma patients. Leuk Res 2007. [DOI: 10.1016/s0145-2126(07)70080-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
19
|
Milani R, Zanni M, Dodero A, Spina F, Testi A, Tarella C, Bernardi M, Gallamini A, Bandini G, Benedetti F, Gianni A, Corradini P. P158 Long-term outcome of therapy-related myelodysplastic syndromes and acute myeloid leukemias arising in patients treated for lymphoma or breast cancer. Leuk Res 2007. [DOI: 10.1016/s0145-2126(07)70228-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
20
|
Ricca I, Rocci A, Zanni M, Dellacasa C, Ruella M, Compagno M, Caracciolo D, Ferrero D, Boccadoro M, Ladetto M, Tarella C. C011 Marked telomere loss following autologous stem cell transplantation may be predictive for the onset of secondary myelodysplastic syndrome/acute leukemia. Leuk Res 2007. [DOI: 10.1016/s0145-2126(07)70049-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
21
|
Ladetto M, Vallet S, Benedetti F, Vitolo U, Martelli M, Callea V, Patti C, Coser P, Perrotti A, Sorio M, Boccomini C, Pulsoni A, Stelitano C, Scimè R, Boccadoro M, Rosato R, De Marco F, Zanni M, Corradini P, Tarella C. Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial. Leukemia 2006; 20:1840-7. [PMID: 16932351 DOI: 10.1038/sj.leu.2404346] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
This study provides an updated report of the consecutive multicenter Gruppo Italiano Trapianto Midollo Osseo trial employing an intensified, purging-free, total body irradiation-free, high-dose sequential chemotherapy schedule with peripheral blood stem cell autograft (i-HDS) in advanced-stage follicular lymphoma (FL). Special interest has been devoted to late toxicities and outcome in terms of molecular status. Ninety-two untreated FL patients aged <or=60 were enrolled by 20 Italian centers and evaluated on an intention-to-treat basis. Main findings are as follows: (1) 5.5-years overall survival projection of 80% (median follow-up: 68 months), with no differences related to age-adjusted IPI score; (2) 46 (50%) of 92 patients presently in continuous complete remission; (3) projected long-term progression-free survival exceeding 80% for patients collecting PCR-negative stem cell harvests or achieving molecular remission within the first 2 years from the end of therapy; (4) actuarial 5-years risk of developing secondary myelodysplasia and acute myeloid leukemia of 3.7%, with most of these events occurring in patients re-treated for recurrent lymphoma. These results demonstrate that i-HDS is feasible, effective and safe even in terms of long-term outcome. As the HDS schedule can be easily supplemented with Rituximab, it is one of the best options for random comparison with Rituximab-supplemented conventional chemotherapy.
Collapse
Affiliation(s)
- M Ladetto
- Divisione Universitaria di Ematologia, Cattedra di Ematologia, Torino, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P, Gianni AM, Rambaldi A, Barbui T, Cortelazzo S. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006; 20:1533-8. [PMID: 16871285 DOI: 10.1038/sj.leu.2404306] [Citation(s) in RCA: 192] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
We report the results of two prospective phase II studies investigating the role of high-dose sequential chemotherapy, followed by autologous stem cell transplantation (ASCT) in 62 patients with advanced stage peripheral T-cell lymphomas (PTCLs) at diagnosis. Conditioning regimen consisted of mitoxantrone (60 mg/m2) and melphalan (180 mg/m2) or carmustine, etoposide, Ara-C and melphalan followed by peripheral blood stem cell autografting. In an intent-to-treat analysis, 46 out of 62 patients (74%) completed the whole programme, whereas 16 patients did not undergo ASCT, mainly because of disease progression. At a median follow-up of 76 months, the estimated 12-year overall (OS), disease-free and event-free survival (EFS) were 34, 55 and 30%, respectively. OS and EFS were significantly better in patients with anaplastic lymphoma-kinase (ALK)-positive anaplastic large-cell lymphoma (ALCL), as compared with the remaining PTCL. Multivariate analysis showed that patients attaining complete remission (CR) before ASCT had a statistically significant benefit in terms of OS and EFS (P<0.0001). Overall treatment-related mortality rate was 4.8%. In conclusion, our findings indicate (1) up-front high-dose therapy and ASCT are feasible, but could induce a high rate of long-term CR only in patients with ALK-positive ALCL and (2) the achievement of CR before autografting is a strong predictor of better survival.
Collapse
Affiliation(s)
- P Corradini
- Divisione di Ematologia, Istituto Nazionale per lo Studio e la Cura dei Tumori, Università di Milano, Milano, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Ricardi U, Filippi AR, Cuttica A, Caracciolo D, Zanni M, Bazzan M, Freilone R, Franco P, Boccadoro M, Tarella C. Rituximab followed by localized radiation therapy in limited stage indolent non-Hodgkin’s lymphoma: Preliminary results of a pilot study. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.6696] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- U. Ricardi
- Univ of Turin, Turin, Italy; Osp Civile di Ciriè, Ciriè (TO), Italy; Osp Evangelico Valdese, Turin, Italy
| | - A. R. Filippi
- Univ of Turin, Turin, Italy; Osp Civile di Ciriè, Ciriè (TO), Italy; Osp Evangelico Valdese, Turin, Italy
| | - A. Cuttica
- Univ of Turin, Turin, Italy; Osp Civile di Ciriè, Ciriè (TO), Italy; Osp Evangelico Valdese, Turin, Italy
| | - D. Caracciolo
- Univ of Turin, Turin, Italy; Osp Civile di Ciriè, Ciriè (TO), Italy; Osp Evangelico Valdese, Turin, Italy
| | - M. Zanni
- Univ of Turin, Turin, Italy; Osp Civile di Ciriè, Ciriè (TO), Italy; Osp Evangelico Valdese, Turin, Italy
| | - M. Bazzan
- Univ of Turin, Turin, Italy; Osp Civile di Ciriè, Ciriè (TO), Italy; Osp Evangelico Valdese, Turin, Italy
| | - R. Freilone
- Univ of Turin, Turin, Italy; Osp Civile di Ciriè, Ciriè (TO), Italy; Osp Evangelico Valdese, Turin, Italy
| | - P. Franco
- Univ of Turin, Turin, Italy; Osp Civile di Ciriè, Ciriè (TO), Italy; Osp Evangelico Valdese, Turin, Italy
| | - M. Boccadoro
- Univ of Turin, Turin, Italy; Osp Civile di Ciriè, Ciriè (TO), Italy; Osp Evangelico Valdese, Turin, Italy
| | - C. Tarella
- Univ of Turin, Turin, Italy; Osp Civile di Ciriè, Ciriè (TO), Italy; Osp Evangelico Valdese, Turin, Italy
| |
Collapse
|
24
|
von Greyerz S, Zanni M, Schnyder B, Pichler WJ. Presentation of non-peptide antigens, in particular drugs, to specific T cells. Clin Exp Allergy 1998; 28 Suppl 4:7-11. [PMID: 9761023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
Drugs are non-peptide antigens that can be recognized by specific T cells. It has been thought for many years that small molecular compounds can only be stimulating for T cells after covalent binding to MHC-embedded peptides. As most drug-specific T cell clones can react to glutaraldehyde fixed antigen presenting cells (APC), recognition of drugs by specific T cells does not require prior uptake and processing of haptenated proteins by APC. In fact, activated T cell clones can recognize drugs associated with the MHC-peptide complex in a non-covalent way. Such a binding is reminiscent of superantigen stimulations of T cells.
Collapse
Affiliation(s)
- S von Greyerz
- Institute of Immunology and Allergology, Inselspital, Bern, Switzerland
| | | | | | | |
Collapse
|
25
|
Cabib S, Giardino L, Calzá L, Zanni M, Mele A, Puglisi-Allegra S. Stress promotes major changes in dopamine receptor densities within the mesoaccumbens and nigrostriatal systems. Neuroscience 1998; 84:193-200. [PMID: 9522373 DOI: 10.1016/s0306-4522(97)00468-5] [Citation(s) in RCA: 76] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
This study investigated the effects of stress on brain dopamine receptor densities in two inbred strains of mice. Analysis of [3H]SCH23390 binding by quantitative autoradiography revealed that repeated restraint stress significantly increases D1-like receptor density in the nucleus accumbens of mice of the DBA/2 strain whist reducing it in the caudate-putamen of C57BL/6 mice. No significant changes in D2-like receptor quantified by [3H](-)-sulpiride binding were observed in caudate, substantia nigra and accumbens of stressed C57BL/6 mice. Instead, in DBA/2 mice, stress significantly increased D2-like receptor density in the nucleus accumbens whilst reducing it in the substantia nigra. Finally, stress significantly increased D2-like receptor density within the ventral tegmental area of C57BL/6 mice whilst significantly reducing it in mice of the DBA/2 strain. These results indicate that stress promotes major changes in mesoaccumbens and nigrostriatal dopamine receptor densities. The direction of these changes depends on receptor subtype, brain area and strain. Moreover, the opposite changes of D2-like receptor densities promoted by stress in the ventral tegmental area of the two inbred strains of mice suggest that mesoaccumbens dopamine autoreceptors density might be controlled by a major genotype x stress interaction.
Collapse
Affiliation(s)
- S Cabib
- Institute Psicobiologia e Psicofarmacologia, Rome, Italy
| | | | | | | | | | | |
Collapse
|
26
|
Calzà L, Pozza M, Zanni M, Manzini CU, Manzini E, Hökfelt T. Peptide plasticity in primary sensory neurons and spinal cord during adjuvant-induced arthritis in the rat: an immunocytochemical and in situ hybridization study. Neuroscience 1998; 82:575-89. [PMID: 9466462 DOI: 10.1016/s0306-4522(97)00272-8] [Citation(s) in RCA: 94] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Chronic polyarthritis due to complete Freund's adjuvant injection is characterized by severe inflammation and pain. In the present immunocytochemical and in situ hybridization study on the rat, we quantitatively investigated peptide and peptide messenger RNA expression in the sensory circuit at the spinal level, i.e. sensory neurons in the dorsal root ganglia and in nerve endings and local neurons in the dorsal horn of the spinal cord. The immunocytochemical experiments were carried out five, 13 and 21 days after complete Freund's adjuvant injection, whereas in situ hybridization study was performed after 21 days from complete Freund's adjuvant injection. The main results in the present study are the following: (i) a decrease in substance P-, calcitonin gene-related peptide- and galanin-like immunoreactivities in dorsal root ganglia is observed five days after complete Freund's adjuvant injection, with recovery (calcitonin gene-related peptide and galanin) or even an increase (substance P) after 21 days; (ii) calcitonin gene-related peptide, substance P and galanin peptide levels are increased in dorsal root ganglia after 21 days; (iii) opioid peptide (enkephalin and dynorphin), substance P and galanin messenger RNAs are strongly up-regulated in dorsal horn neurons after 21 days; (iv) neuropeptide Y content increases in dorsal root fibres and neuropeptide Y messenger RNA levels decrease in spinal neurons after 21 days; and (v) a dramatic decrease in calcitonin gene-related peptide and cholecystokinin messenger RNA levels is found in motoneurons in the ventral horn after 21 days. These data indicate that peptide expression in dorsal root ganglia and the spinal cord is markedly influenced by severe inflammation with distinct and individual temporal patterns, which are also related to the severe rearrangement of joint structure during polyarthritis. The increase in galanin levels in dorsal root ganglia 21 days after complete Freund's adjuvant injection can be related to the structural damage of nerve fibres. Thus, there may be a transition from inflammatory to neuropathic pain, which could have consequences for treatment of patients with rheumatoid arthritis.
Collapse
Affiliation(s)
- L Calzà
- Institute of Human Physiology, University of Cagliari, Italy
| | | | | | | | | | | |
Collapse
|
27
|
Giardino L, Zanni M, Pozza M, Bettelli C, Covelli V. Dopamine receptors in the striatum of rats exposed to repeated restraint stress and alprazolam treatment. Eur J Pharmacol 1998; 344:143-7. [PMID: 9600648 DOI: 10.1016/s0014-2999(97)01608-7] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Stress-related behaviors are accompanied by modification of a large number of neurotransmitters in the brain. Moreover, the binding to GABA(A) receptors does not account for all the effects of benzodiazepines. In this study we investigated the effect of repeated restraint stress and alprazolam treatment (1 mg/day os) on dopamine receptors (Bmax and Kd) in the striatum of adult rats by means of quantitative receptor autoradiography. After chronic restraint stress dopamine D1 receptors (Bmax value) decreased in the accumbens nucleus, whereas dopamine D2 receptors were not modified in any investigated area. After alprazolam treatment, a considerable increase in both dopamine D1 and D2 receptors in the striatum was observed. Chronic immobilization stress together with alprazolam treatment re-established dopamine D1 receptor density to control values in the accumbens nucleus and olfactory tubercle, whereas it resulted in an increase in dopamine D2 receptors comparable to that elicited by alprazolam treatment alone.
Collapse
Affiliation(s)
- L Giardino
- Inst. of Otolaryngology II, University of Milano, Italy.
| | | | | | | | | |
Collapse
|
28
|
Schnyder B, Mauri-Hellweg D, Zanni M, Bettens F, Pichler WJ. Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones. J Clin Invest 1997; 100:136-41. [PMID: 9202065 PMCID: PMC508173 DOI: 10.1172/jci119505] [Citation(s) in RCA: 219] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
T cells can recognize small molecular compounds like drugs. It is thought that covalent binding to MHC bound peptides is required for such a hapten stimulation. Sulfamethoxazole, like most drugs, is not chemically reactive per se, but is thought to gain the ability to covalently bind to proteins after intracellular drug metabolism. The purpose of this study was to investigate how sulfamethoxazole is presented in an immunogenic form to sulfamethoxazole-specific T cell clones. The stimulation of four CD4(+) and two CD8(+) sulfamethoxazole-specific T cell clones by different antigen-presenting cells (APC) was measured both by proliferation and cytolytic assays. The MHC restriction was evaluated, first, by inhibition using anti-class I and anti-class II mAb, and second, by the degree of sulfamethoxazole-induced stimulation by partially matched APC. Fixation of APC was performed with glutaraldehyde 0.05%. The clones were specific for sulfamethoxazole without cross-reaction to other sulfonamides. The continuous presence of sulfamethoxazole was required during the assay period since pulsing of the APC was not sufficient to induce proliferation or cytotoxicity. Stimulation of clones required the addition of MHC compatible APC. The APC could be fixed without impairing their ability to present sulfamethoxazole. Sulfamethoxazole can be presented in an unstable, but MHC-restricted fashion, which is independent of processing. These features are best explained by a direct, noncovalent binding of sulfamethoxazole to the MHC-peptide complex.
Collapse
Affiliation(s)
- B Schnyder
- Institute of Immunology and Allergology, Inselspital, CH-3010-Bern, Switzerland
| | | | | | | | | |
Collapse
|
29
|
Pichler WJ, Zanni M, von Greyerz S, Schnyder B, Mauri-Hellweg D, Wendland T. High IL-5 production by human drug-specific T cell clones. Int Arch Allergy Immunol 1997; 113:177-80. [PMID: 9130515 DOI: 10.1159/000237539] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
To analyze whether and how T cells are involved in drug allergies, we analyzed the drug-induced activation of T cell subsets, T cell receptor V-beta usage and cytokine secretion of T cells from the peripheral blood of drug-allergic individuals. The specificity of the T cells was demonstrated by specific restimulation of drug specific clones. We found that drugs which do not need to be metabolized to become immunogenic (haptens like penicillin G) can stimulate CD4+ and CD8+ T cells in vitro. The T cell response to penicillin can be oligoclonal (use of a certain T cell receptor Vbeta only) or polyclonal. Only polyclonal T cell lines were cross-reactive with other beta-lactam antibiotics. Sulfamethoxazole and lidocaine are thought to gain their ability to bind to proteins by intracellular drug metabolism. They were found to stimulate CD4+ and CD8+ T cells in vitro, and some reactive T cell lines were oligoclonal. The majority of lidocaine-specific clones secreted rather high amounts of IL-5 and IL-4 after PMA/ionomycin stimulations (Th2-like), but some CD4+ and all CD8+ clones had a Th1-like phenotype (high INF-gamma and TNF-alpha). The data clearly demonstrate the existence of drug-specific alphabeta+ T cells in the circulation of drug-allergic individuals and reveal a great heterogeneity of T-cell-mediated responses. Further studies are needed to correlate the type of T cell response to the clinical picture, which can be quite heterogeneous.
Collapse
Affiliation(s)
- W J Pichler
- Institute of Immunology and Allergology, Inselspital, Bern, Switzerland
| | | | | | | | | | | |
Collapse
|
30
|
|
31
|
Abstract
Anatomical, lesion and functional studies have indicated that the mesostriatal dopaminergic (DAergic) system may serve as supravestibular center in posture and locomotion control. Nevertheless, no data are available on the involvement of DAergic systems during vestibular compensation. This study was designed for the analysis of DA1 and DA2 receptors in the striatum by means of quantitative receptor autoradiography 28 days after unilateral or bilateral lesion of the labyrinth in 3-month-old rats. Considering the severe decline of DA content and receptors in striatum and the difference in behavioral recovery after vestibular lesions in old age, we also analyzed 24-month-old, lesioned and unlesioned rats. In young rats, hemilabyrinthectomy caused a bilateral increase (20-30%) of DA1 receptors and a two-fold increase of DA2 receptors. In old-rats, we observed a similar modification of DA2 receptors, and a 50% increase in DA1 receptors. Bilabyrinthectomy did not modify DA1 receptor density and decreased DA2 receptor density in young animals, whereas it produced an increase in both DA1 and DA2 in old rats. This study provides evidence for the involvement of the DAergic system during vestibular compensation. Our results also indicate great biochemical plasticity of the remaining DA receptors in the striatum of old rats.
Collapse
Affiliation(s)
- L Giardino
- Institute of Otolaryngology II, University of Milano, Italy.
| | | | | |
Collapse
|
32
|
Giardino L, Zanni M, Bettelli C, Savina MA, Calzà L. Regulation of glutamic acid decarboxylase mRNA expression in rat brain after sertraline treatment. Eur J Pharmacol 1996; 312:183-7. [PMID: 8894594 DOI: 10.1016/0014-2999(96)00588-2] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
We now investigated the effect of chronic treatment with sertraline on glutamic acid decarboxylase mRNA expression in different rat brain areas by means of in situ hybridization. We found a reduced glutamic acid decarboxylase mRNA expression in the prefrontal cortex, accumbens nucleus, olfactory tubercle and reticular nucleus of the thalamus. The involvement of presynaptic modulation of gamma-amino-butyric acid transmission in the anxiolytic effect of sertraline is discussed.
Collapse
Affiliation(s)
- L Giardino
- Inst. of Otolaryngol. II, Milano University, Italy.
| | | | | | | | | |
Collapse
|
33
|
Mauri-Hellweg D, Zanni M, Frei E, Bettens F, Brander C, Mauri D, Padovan E, Weltzien HU, Pichler WJ. Cross-reactivity of T cell lines and clones to beta-lactam antibiotics. J Immunol 1996; 157:1071-9. [PMID: 8757611] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
To clarify on a molecular level the specific T cell response to haptens like penicillin G, we generated T cell lines and clones from penicillin-allergic patients. Two types of beta-lactam reactivity of T cells could be delineated: one group of patients showed a rather restricted specificity, as the penicillin-elicited T cell lines generated from such donors proliferated only to the stimulating penicillin, but not to other beta-lactam antibiotics nor to cephalosporines, even if the side chain was identical. This indicates that the penicilloyl structure together with the side chain was recognized by these T cells. The second group comprised patients with more broadly reactive T cells, as they were restimulated by penicillin G as well as by related penicillins like amoxicillin or ampicillin, but not cephalosporines. This indicates that the penicilloyl structure, a common motif of penicillins, was important for T cell recognition. Clones generated from a broadly reactive patient confirmed this heterogeneity, as either monospecific or broadly specific T cell clones could be identified. This broad or very restricted pattern of T cell reactivity was reflected in the use of TCR Vbeta-chains: while the broadly reactive T cell lines showed a heterogenous TCR usage, the highly restricted T cell lines showed an up-regulation of one TCR Vbeta-chain. Thus, our data suggest that the outgrowth of T cells bearing a certain TCR Vbeta may be a sign of a limited cross-reactivity.
Collapse
Affiliation(s)
- D Mauri-Hellweg
- Institute of Immunology and Allergology, Inselspital, Bern, Switzerland
| | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Mauri-Hellweg D, Zanni M, Frei E, Bettens F, Brander C, Mauri D, Padovan E, Weltzien HU, Pichler WJ. Cross-reactivity of T cell lines and clones to beta-lactam antibiotics. The Journal of Immunology 1996. [DOI: 10.4049/jimmunol.157.3.1071] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Abstract
To clarify on a molecular level the specific T cell response to haptens like penicillin G, we generated T cell lines and clones from penicillin-allergic patients. Two types of beta-lactam reactivity of T cells could be delineated: one group of patients showed a rather restricted specificity, as the penicillin-elicited T cell lines generated from such donors proliferated only to the stimulating penicillin, but not to other beta-lactam antibiotics nor to cephalosporines, even if the side chain was identical. This indicates that the penicilloyl structure together with the side chain was recognized by these T cells. The second group comprised patients with more broadly reactive T cells, as they were restimulated by penicillin G as well as by related penicillins like amoxicillin or ampicillin, but not cephalosporines. This indicates that the penicilloyl structure, a common motif of penicillins, was important for T cell recognition. Clones generated from a broadly reactive patient confirmed this heterogeneity, as either monospecific or broadly specific T cell clones could be identified. This broad or very restricted pattern of T cell reactivity was reflected in the use of TCR Vbeta-chains: while the broadly reactive T cell lines showed a heterogenous TCR usage, the highly restricted T cell lines showed an up-regulation of one TCR Vbeta-chain. Thus, our data suggest that the outgrowth of T cells bearing a certain TCR Vbeta may be a sign of a limited cross-reactivity.
Collapse
Affiliation(s)
- D Mauri-Hellweg
- Institute of Immunology and Allergology, Inselspital, Bern, Switzerland
| | - M Zanni
- Institute of Immunology and Allergology, Inselspital, Bern, Switzerland
| | - E Frei
- Institute of Immunology and Allergology, Inselspital, Bern, Switzerland
| | - F Bettens
- Institute of Immunology and Allergology, Inselspital, Bern, Switzerland
| | - C Brander
- Institute of Immunology and Allergology, Inselspital, Bern, Switzerland
| | - D Mauri
- Institute of Immunology and Allergology, Inselspital, Bern, Switzerland
| | - E Padovan
- Institute of Immunology and Allergology, Inselspital, Bern, Switzerland
| | - H U Weltzien
- Institute of Immunology and Allergology, Inselspital, Bern, Switzerland
| | - W J Pichler
- Institute of Immunology and Allergology, Inselspital, Bern, Switzerland
| |
Collapse
|
35
|
Zanni M, Tamburro A, Rotilio D. IL-1 beta and TGF-beta 1 modulate the sulphation grade of chondro-disaccharides in porcine articular cartilage: a capillary electrophoresis study. J Lipid Mediat Cell Signal 1995; 12:29-44. [PMID: 7551687 DOI: 10.1016/0929-7855(95)00005-b] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
This report describes the effect of interleukin-1 beta (IL-1 beta) and transforming growth factor-beta 1 (TGF-beta 1) on proteoglycan release from cartilage explants and modification at the sulphation level. Matrix proteoglycans purified by ion-exchange chromatography were composed of two distinct peaks (1 and 2) each showing a different Kav value when they were subjected to size-exclusion chromatography on a Sepharose CL-2B column. Glycosaminoglycans (GAGs) of conditioned medium and extracellular matrix proteoglycans were digested by chondroitin ABC and AC lyase, suggesting that chondroitin sulphate (CS) is the major GAG present (80-90%). Structural analysis of disaccharides, by capillary zone electrophoresis, revealed a different pattern of sulphated glycosaminoglycans when cartilage was treated with either IL-1 beta or TGF-beta 1. Analysis of GAGs released into the medium from TGF-beta 1 treated cartilage showed a reduction in the level of 4-S-disaccharide (delta Di4S) and an increase in non-sulphated disaccharides (delta Di0S), while no significant changes were found in IL-1 beta treated cartilage. In the extracellular matrix, IL-1 beta and TGF-beta 1 induced a more complex rearrangement of the GAGs. The level of non-sulphated disaccharides was increased whereas that of total sulphated disaccharides was reduced. Taken together, these results suggest that both cytokines modify the structure of GAGs, probably by interfering with the activity or the synthesis of sulphotransferases involved in GAG turnover.
Collapse
Affiliation(s)
- M Zanni
- Istituto di Ricerche Farmacologiche Mario Negri, Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy
| | | | | |
Collapse
|
36
|
Zanni M, Giardino L, Toschi L, Galetti G, Calzà L. Distribution of neurotransmitters, neuropeptides, and receptors in the vestibular nuclei complex of the rat: an immunocytochemical, in situ hybridization and quantitative receptor autoradiographic study. Brain Res Bull 1995; 36:443-52. [PMID: 7712206 DOI: 10.1016/0361-9230(94)00193-5] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
This article investigates the distribution of neurotransmitters, neuropeptides, and related receptors in the vestibular nuclei complex (VNC) of the adult rat by means of immunohistochemistry, in situ hybridization, and quantitative receptor autoradiography. The entire complex proves to be rich in muscarinic receptors and it shows a high density of imipramine and benzodiazepine binding sites. Peptidergic neurons and a few positive fibers are described in the caudal part of the VNC. In particular, the medial vestibular nucleus contains a number of neurons expressing both the enkephalin mRNA and peptide. This nucleus and the lateral vestibular nucleus are also rich in opiate receptors. Substance P, thyrotropin releasing hormone, and neurotensin receptors are also found in the medial and in the spinal vestibular nuclei. In spite of the presence of alpha 2 catecholaminergic receptors, no thyrosine-hydroxylase-immuno-reactive elements are seen in the caudal VNC. The possible functional meaning of these data is discussed.
Collapse
Affiliation(s)
- M Zanni
- Institute of Otolaryngology, University of Modena, Italy
| | | | | | | | | |
Collapse
|
37
|
Peracchia F, Tamburro A, Zanni M, Rotilio D. Effects of thrombin and thrombin peptide activating receptor (SFLLRN) on proteoglycan synthesis and distribution in human endothelial cells. Biochem Biophys Res Commun 1994; 205:1625-31. [PMID: 7811245 DOI: 10.1006/bbrc.1994.2853] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
In the present study we compared the effect of alpha-thrombin and the active receptor peptide (SFLLRN) on proteoglycan (PG) release from human endothelial cells (HUVEC) exposed for 24 h in the presence of 35S-sulfate and 3H-glucosamine. The effect of thrombin (5U/ml) and receptor peptide (100 microM) was evaluated on the distribution of PGs in the conditioned medium, cellular extract and extracellular matrix. In the conditioned medium, thrombin increased the amount of PGs. In extracellular matrix thrombin decreased radioactive PGs measured by both isotopes; no difference was observed in cell extracts. SFLLRN peptide showed a consistent increase in PG content in the medium. At variance with thrombin, in cell extracts the peptide increased the amount of PGs. No relevant differences were observed in PG content of extracellular matrix. These results indicate that thrombin and the peptide act differently on PG distribution and underline the different role of the serine protease and of the receptor binding activities of thrombin.
Collapse
Affiliation(s)
- F Peracchia
- Istituto di Ricerche Farmacologiche Mario Negri Consorzio Mario Negri Sud, S. Maria Imbaro, Italy
| | | | | | | |
Collapse
|
38
|
Giardino L, Ceccatelli S, Zanni M, Hökfelt T, Calzà L. Regulation of VIP mRNA expression by thyroid hormone in different brain areas of adult rat. Brain Res Mol Brain Res 1994; 27:87-94. [PMID: 7877459 DOI: 10.1016/0169-328x(94)90188-0] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
A role of thyroid hormone in the regulation of neuropeptide synthesis has been demonstrated in different tissues. In this paper we investigated the vasoactive intestinal peptide (VIP) mRNA expression by means of in situ hybridization in several brain areas of hypo- and hyperthyroid adult rats. Neither hypo- nor hyperthyroidism modified the VIP mRNA levels in the thalamus and in the hypothalamic suprachiasmatic nucleus. In contrast, in the anterior cingulate and frontoparietal motor cortex of hypothyroid rats there was a marked increase in the signal for VIP mRNA per cell, but the number of VIP expressing neurons did not change. These data indicate that also central VIP synthesis can be influenced by the levels of circulating thyroid hormone, but that this effect is confined to specific areas and cell populations of the brain.
Collapse
Affiliation(s)
- L Giardino
- Institute of Otolaryngology, University of Milan, Italy
| | | | | | | | | |
Collapse
|
39
|
Zanni M, Tamburro A, Santone I, Rotilio D. Modulation by transforming growth factor-beta 1 and interleukin-1 beta of proteoglycan release and chondrodisaccharide composition in porcine articular cartilage. Semin Thromb Hemost 1994; 20:159-67. [PMID: 7997887 DOI: 10.1055/s-2007-1001899] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The effects of IL-1 beta and TGF-beta 1 on proteoglycan release and modifications in porcine articular cartilage explants are described. Proteoglycan release in culture medium was markedly increased when cartilage was treated with IL-1 beta (5 to 100 ng/mL). Addition of IL-1 beta alone or in combination with TGF-beta 1 to cartilage culture stimulated the production and release of PGE2. Indomethacin (10(-6) M) did not modify the IL-1 beta effect on proteoglycan release. Both the spontaneous and IL-1 beta-induced proteoglycan release were downregulated by TGF-beta 1 (50 ng/mL). Basal and stimulated loss of proteoglycans was reduced by the addition of cycloheximide (10(-6) M) and by metalloprotease inhibitors. GAGs of conditioned medium and extracellular matrix proteoglycans were digested to about 90% by chondroitin ABC lyase, suggesting that CS is the major GAG present. Structural analysis of disaccharides, by CZE, revealed a different pattern of oxysulfation when cartilage explants were treated either with IL-1 beta or TGF-beta 1. Indeed, analysis of GAGs, released into the medium from TGF-beta 1-treated cartilage, showed a reduction in the level of 4-S-disaccharide (delta Di4S and an increase in desulfated disaccharides delta Di0S). In the extracellular matrix, IL-1 beta and TGF-beta 1 induced a more complex rearrangement of the GAGs, in that the levels of delta Di0S and delta Di4S were increased whereas those of delta Di6S were decreased. Altogether, these results suggest that TGF-beta 1 does not only counteract the effect of IL-1 beta on proteoglycan release, but modifies the structure of GAGs, probably by interfering with the activity or the synthesis of sulfotranspherases involved in GAG biosynthesis.
Collapse
Affiliation(s)
- M Zanni
- Istituto di Ricerche Farmacologiche Mario Negri, Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy
| | | | | | | |
Collapse
|
40
|
Pincelli C, Fantini F, Giardino L, Zanni M, Calzá L, Sevignani C, Giannetti A. Autoradiographic detection of substance P receptors in normal and psoriatic skin. J Invest Dermatol 1993; 101:301-4. [PMID: 7690377 DOI: 10.1111/1523-1747.ep12365423] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Substance P has been detected in human skin and has been implicated in the pathogenesis of certain inflammatory cutaneous disorders. However, little is known about the number and distribution of substance P binding sites in the skin. Receptor autoradiography was employed to detect and quantitate substance P receptors in normal as well as psoriatic skin. Substance P binding sites were distributed in the epidermis and dermis both in normal and psoriatic skin. In the dermis, the highest densities of SP binding sites were found in the areas corresponding to the dermal papillae and the adnexal structures. Quantitative analysis revealed that saturable binding was obtained both in the epidermis and in the labeled dermal areas. Rosenthal plot values were consistent with a single population of binding sites. No difference in the binding measurements was observed between normal and psoriatic skin. The presence of substance P receptors in the epidermis and in the dermal papillae raises interesting issues on the possible targets of this peptide in human skin both under physiologic and pathologic conditions.
Collapse
Affiliation(s)
- C Pincelli
- Institute of Dermatology, University of Modena, Italy
| | | | | | | | | | | | | |
Collapse
|
41
|
Petraglia F, Calzà L, Giardino L, Zanni M, Florio P, Ferrari AR, Nappi C, Genazzani AR. Maternal decidua and fetal membranes contain immunoreactive neuropeptide Y. J Endocrinol Invest 1993; 16:201-5. [PMID: 8514975 DOI: 10.1007/bf03344947] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The aim of the present study was to evaluate whether the various intrauterine tissues contain immunoreactive neuropeptide Y (NPY). Previous observations showed that human placenta produces NPY and that it may play a local role. Using a polyclonal NPY antiserum and an immunofluorescent technique, sections of maternal decidua, amnion and chorion collected from a pregnant women at parturition were studied. An intense positive staining for NPY was observed in epithelial amnion cells and in chorionic cytotrophoblast. Some of the maternal decidual cells showed a weaker signal of immunoreactive NPY. In evaluating whether NPY may coexist with other hormones in these tissues, adjacent slices of decidua, amnion and chorion were stained with activin beta B subunit antiserum. In the various tissues a relevant number of cells showed positive signals for both NPY and activin. The present findings showed that the various intrauterine tissues contain NPY and that in a large number of cells of amnion, chorion and decidua the neuropeptide is colocalized with immunoreactive activin. In view of the physiological implications of NPY in the regulation of uterine contractility and of placental hormonogenesis, the present findings indicate a large distribution of NPY in the various intrauterine tissues.
Collapse
Affiliation(s)
- F Petraglia
- Clinica Ostetrica e Ginecologica, Università di Modena, Italy
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Abstract
In this paper we describe the modification of benzodiazepine (BDZ) binding sites in the rat brain after different times of treatment with the 5-hydroxytryptamine-(5HT) uptake blocker sertraline. We investigated the effect of 8, 15 and 30 days sertraline treatment (10 mg/kg/day, i.p.) on 3 H-flunitrazepam binding sites. In order to describe the anatomical site of action of the drug, the experiment has been carried out by means of quantitative receptor autoradiography. After 8 days of sertraline treatment, an increase of BDZ receptor density is found in the olfactory tubercle. This effect is reversed at 15 and 30 days. At 15 days of treatment, an increase is found in the anterior cingulate cortex. This increase is still present after 30 days of treatment. At 30 days of treatment, we also found an increase of BDZ receptor density in the frontoparietal motor cortex and in the septal nuclei. The Scatchard plots obtained from the saturation experiments indicate that this increase of the receptor density is due to an increase of both the receptor number and affinity. All the other investigated areas are unaffected by the sertraline treatment. The possible neurochemical basis of these BDZ receptor regulation by sertraline and its influence in the therapeutical profile are discussed.
Collapse
Affiliation(s)
- L Giardino
- Institute of Human Physiology, Medical School, University of Cagliari, Italy
| | | | | | | | | |
Collapse
|
43
|
Calzá L, Giardino L, Ceccatelli S, Zanni M, Elde R, Hökfelt T. Distribution of thyrotropin-releasing hormone receptor messenger RNA in the rat brain: an in situ hybridization study. Neuroscience 1992; 51:891-909. [PMID: 1488129 DOI: 10.1016/0306-4522(92)90528-a] [Citation(s) in RCA: 59] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Based on the recent cloning of the mouse thyrotropin-releasing hormone receptor, oligonucleotide probes complementary to the DNA sequence were constructed and used for in situ hybridization studies on the rat brain. Thyrotropin-releasing hormone receptor messenger RNA was found in many areas of the brain, mostly showing high degree of overlap with the distribution thyrotropin-releasing hormone binding sites as previously revealed in autoradiographic studies. Thus, a strong signal was observed in the accessory olfactory bulb, the perirhinal sulcus, the ventral aspects of the hippocampal formation, some amygdaloid nuclei, the diagonal band nucleus, parts of nucleus accumbens, the bed nucleus of the stria terminalis, dorsomedial, lateral and perifornical hypothalamic regions, the septohippocampal nucleus, parts of the vestibular complex, as well as many bulbar motoneurons including the facial, dorsal vagal, ambiguus and hypoglossal nuclei, the superficial layer of the spinal trigeminal nucleus, and motoneurons and dorsal horn neurons in the spinal cord. Cells within one and the same nucleus expressed varying levels of thyrotropin releasing hormone receptor messenger RNA suggesting marked differences in rate of receptor synthesis. Most of these areas receive an input by thyrotropin-releasing hormone-positive nerve endings. Taken together these results suggest that thyrotropin-releasing hormone receptors are mostly localized in the vicinity of the cell bodies which express thyrotropin-releasing hormone receptor messenger RNA and mediate the wide range of actions that have been recorded after administration of exogenous thyrotropin-releasing hormone.
Collapse
Affiliation(s)
- L Calzá
- Institute of Human Physiology, University of Cagliari, Italy
| | | | | | | | | | | |
Collapse
|
44
|
Calzà L, Giardino L, Zanni M, Galetti G. Muscarinic and gamma-aminobutyric acid-ergic receptor changes during vestibular compensation. A quantitative autoradiographic study of the vestibular nuclei complex in the rat. Eur Arch Otorhinolaryngol 1992; 249:34-9. [PMID: 1314614 DOI: 10.1007/bf00175668] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Involvement of the neurotransmitters acetyl choline and gamma-aminobutyric acid (GABA) in vestibular compensation has been suggested by electrophysiological and pharmacological experiments. In this investigation we used quantitative autoradiography to study the modification of muscarinic and benzodiazepine receptors in each nucleus of the rat's vestibular nucleus complex. Tissues were examined 3, 14, 23 h and 3, 12, 37 and 90 days after unilateral surgical labyrinthectomies. The present results demonstrated a muscarinic receptor supersensitivity in the deafferented side in the superior vestibular nucleus 90 days after surgery. This increase was not large enough to support the cholinergic receptor supersensitivity hypothesis for vestibular compensation. The changes in the benzodiazepine receptors observed for a short time following surgery were reversed after a few days. These findings support a transient involvement of GABAergic pathways in vestibular compensation.
Collapse
Affiliation(s)
- L Calzà
- Institute of Human Physiology, University of Cagliari Medical School, Italy
| | | | | | | |
Collapse
|
45
|
Marozzi F, Codini G, Trombini M, Zoja R, Caccavo D, Gilardi S, De Micheli M, Salvioni P, Ferraguti P, Zanni M. [Acute narcotic addiction deaths in Milan in the years 1985 and 1988: a comparison of diverse trends of the phenomenon]. Ann Ig 1991; 3:359-67. [PMID: 1726628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- F Marozzi
- Ist. di Medicina Legale delle Assicurazioni, Università di Milano
| | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Giardino L, Calzà L, Piazza PV, Zanni M, Amato G. DA2/NT receptor balance in the mesostriatal and mesolimbocortical systems after chronic treatment with typical and atypical neuroleptic drugs. Brain Res 1990; 532:140-5. [PMID: 1980851 DOI: 10.1016/0006-8993(90)91753-4] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Typical and atypical neuroleptic drugs show several clinical and behavioral effects, possibly related to the different anatomical sites of the action in the mesolimbocortical or mesostriatal dopaminergic systems. Because of the interaction between dopamine (DA) and neurotensin (NT) in the target areas of these systems, and in order to study if the different action of typical and atypical neuroleptic drugs could be related to a modification of the DA/NT balance, we investigated DA2 and NT receptor modifications--by means of quantitative receptor autoradiography--after chronic treatment with low dosage of haloperidol, chlorpromazine, thioridazine and clozapine. We described a decrease of NT receptor density in the target areas of the mesolimbocortical system produced by all the treatments. This effect does not match with DA2 receptor modifications. On the contrary, the block of DA transmission obtained by high dosage of haloperidol induces an increase of NT receptor density. Our results further demonstrate the regulation of NT transmission by DAergic drugs.
Collapse
Affiliation(s)
- L Giardino
- Institute of Human Physiology, Medical School, Cagliari, Italy
| | | | | | | | | |
Collapse
|
47
|
Calzá L, Giardino L, Zanni M, Velardo A, Parchi P, Marrama P. Daily changes of neuropeptide Y-like immunoreactivity in the suprachiasmatic nucleus of the rat. Regul Pept 1990; 27:127-37. [PMID: 2408111 DOI: 10.1016/0167-0115(90)90211-e] [Citation(s) in RCA: 44] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Most of the biochemical, physiological and behavioural events in living organisms show diurnal fluctuations, normally synchronized with 24-h environmental rhythms, such as the light-dark cycle. The suprachiasmatic nucleus (SCN) of the hypothalamus is considered to be a pacemaker of the circadian rhythms in several mammals. The light-dark cycle is the primary synchronizing agent for many of the circadian rhythms which are regulated by the SCN. The photic information reaches the SCN also through a neuropeptide Y(NPY)-like immunoreactive pathway from the ventro-lateral geniculate nucleus. We found that in 12-h-dark and 12-h-light housed rats the NPY-like immunoreactive innervation of the ventro-lateral part of the SCN shows a 24 h rhythm with values rising gradually during the light phase and falling during the dark phase. Besides this rhythm, we found two peaks corresponding to the switching on and switching off of the light. The average level of NPY-like immunoreactivity, as assessed by means of semiquantitative immunocytochemistry and expressed in 'arbitrary units', is reduced in rats housed in total darkness for 2 weeks. These results confirm the physiological role of NPY in the timing of the circadian activity of the SCN.
Collapse
Affiliation(s)
- L Calzá
- Institute of Human Physiology, Medical School, University of Cagliari, Italy
| | | | | | | | | | | |
Collapse
|
48
|
Giardino L, Calzà L, Piazza PV, Zanni M, Sorbera F, Amato G. Opiate receptor modifications in the rat brain after chronic treatment with haloperidol and suipiride. J Psychopharmacol 1990; 4:7-12. [PMID: 22282921 DOI: 10.1177/026988119000400102] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Anatomical, electrophysiological and pharmacological data support the existence of a pronounced interaction between dopamine (DA) and opioids. In particular, chronic administration of DA antagonist drugs modifies opiate peptides and opiate receptors. In this paper we focused, by means of quantitative receptor autoradiography, on the modifications induced by chronic neuroleptic treatment, in patches versus diffuse distribution, of opiate receptors in the striatum, and we also studied the different effects of haloperidol and sulpiride on striatal and cortical receptors. We found a significant decrease of the number of (3H)- naloxone binding sites in the striatal patches of treated animals but no effects in the matrix. We also observed, in haloperidol-treated animals, an increase of (3H)-naloxone binding sites in the medial cortex, and in sulpiride-treated animals an increase in the lateral and dorsal cortex. Two main observations arise from our data: (a) a differential effect is produced by neuroleptic treatment on opiate receptors in patches and in matrix; (b) an opposite influence is exerted by sulpiride and haloperidol on opiate receptors in the cortex and in striatum.
Collapse
Affiliation(s)
- L Giardino
- Institute of Human Physiology, Via Porcell 4, 09100 Cagliari
| | | | | | | | | | | |
Collapse
|
49
|
Calzá L, Giardino L, Battistini N, Zanni M, Galetti S, Protopapa F, Velardo A. Increase of neuropeptide Y-like immunoreactivity in the paraventricular nucleus of fasting rats. Neurosci Lett 1989; 104:99-104. [PMID: 2682395 DOI: 10.1016/0304-3940(89)90336-4] [Citation(s) in RCA: 75] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
The paraventricular nucleus (PVH) of the hypothalamus is a key region for the control of food intake. It presents a very high neuropeptide Y (NPY)-like positive innervation. In this paper we have studied the modifications of NPY-positive innervation in the PVH of 72 h starved rats vs control rats by means of semiquantitative immunocytochemistry. We observed a significant increase of NPY-like immunoreactivity in fasting rats. This result suggests a physiological role of NPY in the food intake regulation at the PVH level.
Collapse
Affiliation(s)
- L Calzá
- Institute of Human Physiology, Cagliari, Italy
| | | | | | | | | | | | | |
Collapse
|
50
|
Giardino L, Calzá L, Zanni M, Velardo A, Pantaleoni M, Marrama P. Daily modifications of 3H-naloxone binding sites in the rat brain: a quantitative autoradiographic study. Chronobiol Int 1989; 6:203-16. [PMID: 2553282 DOI: 10.3109/07420528909056920] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
The endogenous opioid peptides, the opiate receptors and several related behaviours, like opioid-mediated analgesia, show daily variations in different animal species including rats. The attempt to correlate the daily rhythm of opiate receptors in the central nervous system (CNS) to opiate related rhythmic phenomena requires an experimental approach with a high anatomical resolution, as the opioid distribution is very heterogeneous. In this paper we present the study of daily variations of 3H-naloxone binding sites in the different regions of the adult male rat brain, performed by means of quantitative autoradiography. Five rats are sacrificed at each investigated time of the day (0200, 0600, 1000, 1400, 1800 and 2200). The ligant is 3H-naloxone (4 nM), the quantification is performed by means of densitometric procedures (image analyzer Tesak VDC 501, computer Digital PDP 11, 3H-microscale). The statistical analysis is performed according to the single Cosinor method and the one-way analysis of variance followed by the multiple range test of Duncan. We analysed 33 different regions of the rat CNS, and the daily variations of opiate receptors are regionally selective. A circadian rhythm is found in the anterior cingulate cortex, hippocampal cortex, periventricular, medial, ventral, reticular and posterior nuclei of the thalamus, rhomboid, gelatinosus and rheuniens nuclei, lateral hypothalamus, locus coeruleus, grey substance of the pons, reticular formation of medulla oblongata, inferior olivary complex, medial part of the nucleus of the solitary tract and nucleus of the spinal tract of the trigeminal nerve. An ultradian rhythm is found in the medial and lateral preoptic areas, in the medial hypothalamus, in the medial and in the lateral nuclei of habenula. No significant variations during 24 hr according to the Cosinor analysis are found in the dorsal and lateral cerebral cortex, striatum, globus pallidus, bed nucleus of the stria terminalis, septal nuclei, lateral nucleus of the thalamus, cochlear nuclei, nucleus of the solitary tract, lateral and caudal parts, dorsal motor nucleus of the vagal nerve, XII and IX nerve nuclei. The amplitude of the daily variations observed ranges from 10 to 40%. Our results demonstrate the high anatomical selectivity of the daily modifications of 3H-naloxone binding sites in the rat CNS. They also indicate that quantitative autoradiography is a suitable and sensitive technique for these studies.
Collapse
Affiliation(s)
- L Giardino
- Institute of Human Physiology, University of Cagliari, Medical School, Italy
| | | | | | | | | | | |
Collapse
|